Veda Giri, MD

Veda N. Giri, MD is a medical oncologist with specialization in clinical cancer genetics. Dr. Giri is Division Chief of Clinical Cancer Genetics for Yale Cancer Center and Smilow Cancer Hospital and Assistant Director of Clinical Cancer Genetics for Yale Cancer Center, where she leads an integrated and comprehensive effort in cancer genetic evaluation to inform precision medicine, tailored cancer screening, and hereditary cancer risk. She is also Director of the Early Onset Cancer Program. In 2023 she was named a Fellow of the American Society of Clinical Oncology (FASCO).

Dr. Giri's research portfolio includes population science studies focused on genetic evaluation of cancer risk, disparities in access to genetic testing and genetic counseling, and implementation research. She has led numerous studies to advance the field of genetic counseling and genetic testing for inherited prostate cancer. Dr. Giri started the first Men’s Genetic Risk Clinic in the US in 2014 focused on genetic evaluation of inherited prostate cancer in the setting of multidisciplinary care. Dr. Giri also co-chaired the 2017 and 2019 Philadelphia Prostate Cancer Consensus Conferences that addressed development of comprehensive frameworks for genetic evaluation and implementation of genetic testing for prostate cancer. She is the Principal Investigator of multiple grant-funded prostate cancer genetic evaluation studies spanning genetic counseling, genetic testing, disparities, behavioral science, and implementation research. As leader of clinical cancer genetics, Dr. Giri plans to expand population science studies across cancer populations and in the community setting.

Dr. Giri received her medical degree from Sidney Kimmel Medical College (previously Jefferson Medical College) and proceeded to complete her residency in Internal Medicine and fellowship in Hematology-Oncology at the University of Michigan. She then completed advanced training in molecular cancer genetics and cancer risk assessment at Fox Chase Cancer Center. She also has a certification in cancer risk assessment from City of Hope Comprehensive Cancer Center. Dr. Giri currently serves on several national committees including the NIH PDQ® Cancer Genetics Editorial Board, ASCO Evidence-Based Medicine Committee, ASCO Cancer Care Delivery Council, ASCO Health Equity and Outcomes Committee, and ASCO Coverage and Reimbursement Steering Committee contributing expertise in cancer risk assessment and genetics at the national level.